drugset / Trial / NCT06324266

Study on the Efficacy and Safety of Low-dose CTX as Maintenance Therapy for MM Unsuitable for Transplantation

NCT06324266

Phase 2/3 Unknown 80 enrolled Jinling Hospital, China
RandomizedParallel-groupOpen-labelTreatment

Summary

The investigators will conduct randomized and controlled clinical studies in order to preliminarily explore the efficacy and safety of low-dose cyclophosphamide and lenalidomide in maintenance therapy for MM that is not suitable for transplantation in the standard-risk group.

Timeline

Start
2023-04-16
Primary completion
2025-12-31
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified 0.1 g
Comparator Lenalidomide Other / unclassified 10 mg

Indications